Rifapentine indications and usage: Difference between revisions
(Created page with "__NOTOC__ {{Rifapentine }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PRIFTIN (RIFAPENTINE) TABLET, FILM COATE...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Indications And Usage== | |||
Rifapentine is indicated for the treatment of pulmonary tuberculosis caused by Mycobacterium tuberculosis. Rifapentine must always be used in combination with one or more antituberculosis drugs to which the isolate is susceptible depending on the phase of treatment [see Dosage and Administration and Clinical Studies . | |||
===Limitations of Use=== | |||
Rifapentine should not be used as a once weekly Continuation Phase regimen in combination with isoniazid in HIV seropositive patients with pulmonary tuberculosis because of a higher rate of failure and/or relapse documented with the presence of rifampin-resistant organisms [see Warnings and Precautions and Clinical Studies ]. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PRIFTIN (RIFAPENTINE) TABLET, FILM COATED [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f768e337-a948-420a-9fbe-9be359c7a170 | publisher = | date = | accessdate = }}</ref> | Rifapentine has not been studied as part of the Initial Phase treatment regimen in HIV seropositive patients with pulmonary tuberculosis. | ||
Rifapentine should not be used as monotherapy in either the initial or the continuation phases of antituberculous treatment.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PRIFTIN (RIFAPENTINE) TABLET, FILM COATED [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f768e337-a948-420a-9fbe-9be359c7a170 | publisher = | date = | accessdate = }}</ref> | |||
Revision as of 03:30, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications And Usage
Rifapentine is indicated for the treatment of pulmonary tuberculosis caused by Mycobacterium tuberculosis. Rifapentine must always be used in combination with one or more antituberculosis drugs to which the isolate is susceptible depending on the phase of treatment [see Dosage and Administration and Clinical Studies .
Limitations of Use
Rifapentine should not be used as a once weekly Continuation Phase regimen in combination with isoniazid in HIV seropositive patients with pulmonary tuberculosis because of a higher rate of failure and/or relapse documented with the presence of rifampin-resistant organisms [see Warnings and Precautions and Clinical Studies ].
Rifapentine has not been studied as part of the Initial Phase treatment regimen in HIV seropositive patients with pulmonary tuberculosis.
Rifapentine should not be used as monotherapy in either the initial or the continuation phases of antituberculous treatment.[1]
References
Adapted from the FDA Package Insert.